NR4A1 and breast cancer: Stratification of our primary analysis by receptor subtype demonstrated that the observed association was present in hormone receptor–positive (OR, 1.11; 95% CI, 1.03-1.19; P = .006) but not hormone receptor–negative (OR, 1.02; 95% CI, 0.86-1.21; P = .83) breast cancer (Figure 2).